At IAG, Image Analysis Group, we are committed to helping biotech and pharma partners efficiently produce ground-breaking research.

We work behind the scenes, using AI and our proprietary platform DYNAMIKA, to ensure that your study model adheres to the new Lugano guidelines while being cost-effective and acutely aware of other ongoing parallel studies.

In this brief article, we will outline some of the key components of imaging clinical trials of lymphoma that IAG takes into consideration.

With these priorities in mind, rest assured that you can trust IAG every step of the way to help you publish research that will forever change the paradigm of lymphoma treatment.

Currently, the World Health Organization has classified roughly 50 types of lymphoma, with each having numerous subtypes. The following priorities must be statistically analyzed and taken into consideration:

1) Accurate diagnosis and staging. Staging must include whether the lymphoma is limited or advanced, and the degree of tumor burden. The immune status of a patient, for example, such as whether they are immunocompetent or immunocompromised, can significantly alter the imaging uptake response and introduce diagnostic errors.

Many chemotherapy drugs cause cytokine stimulation and inflammatory “flairs,” further muddling MRI, CT, and PET scan findings. Certain tissues heal slower, such as osseous bone, which will show prolonged uptake on contrast PET/CT. At IAG, we ensure none of these errors confound your research.

2) Response to therapy. Each patient must be systematically scanned and cataloged as either complete, partial, stable, progressive, or no response. The Lugano guidelines have recently changed how radiologists measure tumor size and therapy response; our team ensures that all patients are accurately cataloged and tracked to alert you at the first sight of relapse or remission response.

Long term, this develops firm thresholds regarding when to de-escalate or increase therapy to ultimately reduce patient toxicity. At IAG, we also guide our partners in how to choose an appropriate end-point, thus determining therapeutic efficacy.

3) Quality metrics. No imaging modality is 100% accurate. CT and PET scan results are often discordant, with radiologists having known subjective image interpretation and intraobserver variability. The use of IAGs artificial intelligence software eliminates this to offer you standardized reporting and acquisition, with ongoing sensitivity and specificity reports.

4) Record and study the nonmeasurables. Pleural effusions, ascites, cutaneous lesions, metabolic changes, aggressive transformations, and infiltrative developments are just a few of the “nonmeasurables” that science currently has yet to elucidate. At IAG, we aim to one day better characterize these developments, making our partners the leaders in lymphoma research.

Since the Ann Arbor staging system was introduced in 1971, the system has undergone four major overhauls, with oncologists and radiologists alike still calling for a unified guideline and simpler assessment. As a prospective partner, we invite you to join IAG as we radically, forever, change this status quo and cure lymphoma.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.

Contact our expert team: imaging.experts@ia-grp.com

Lung cancer is usually diagnosed in advanced stages with majority of patients already presenting metastatic disease. Only 20 % of NSCLC patients have early stage disease at the time of diagnosis, thus being potentially resectable. The current gold standard is lobectomy with hilar and mediastinal lymph-node sampling or dissection. Curative stereotactic body radiotherapy (SABR) should be offered to patients with stage I NSCLC who have clinical comorbidities or are at very high surgery-related risk, and those who refuse to undergo surgical procedure. Post-operative platinum-based chemotherapy is recommended for all patients with stage II and III surgically resected disease. For patients with locally advanced stage NSCLS, there are different recommended options, including

• Surgery followed by adjuvant chemotherapy
• Neoadjuvant chemotherapy followed by surgery
• Neoadjuvant chemo-radiation followed by surgery

Eligibility for pre-operative or post-operative platinum-doublets with or without radiotherapy should be evaluated in the context of an experienced multidisciplinary team.

The diagnostic evaluation initially focuses on careful physical examination and patient’s history, to identify new symptoms or a significant change in the common respiratory symptoms.

In clinical trials, all patients with suspected lung cancer will undergo a non-invasive chest imaging, including X-rays, CT-scan, and if needed positron emission tomography (PET) with fluorodeoxyglucose (FDG).

Conventional contrast-enhanced chest CT-scan is considered the best exam to detect lung cancer, as it provides detailed information on anatomic location, margins, invasion of surrounding structures or chest wall, and mediastinal lymph nodes involvement.

Use of imaging presents a great opportunity for selecting the right patients and enriching the trial.

IAG offers multiple imaging technique solutions, which are utilized in clinical trials both, while scanning patients for inclusion in the clinical studies, and while assessing the efficacy of ongoing treatments.

• CT Imaging – Computed Tomography (CT) scan of the chest area is the keystone of lung cancer imaging based on which further management options are decided.
• SPECT imaging – A single-photon emission computed tomography (SPECT) renders tomographic imaging, which could be a more accurate method for regional valuation by diagnosing radioactivity in all pulmonary lobes, avoiding spatial overlapping.
• ctDNA testing – Without the risks inherent to biopsy, ctDNA can be attained over time permitting for some serial assessments. Numerous clinical studies have furthermore suggested that ctDNA can be used to identify the occurrence of minimal residual disease (MRD) post-surgical resection in various cancer types, especially lung cancer.
• EGFR/ALK/ROS/BRAF testing – For targeted therapies, with Mechanism of actions targeting multiple mutations in non-small-cell lung cancer (NSCLC) patients, EGFR/ALK/ROS/BRAF testing imaging techniques are useful to assess the patients for eligibility in the trial as well to assess the treatment efficacy.
• MRI and ECG – MRI and ECG scans are typically utilized to assess the organ functions, before including patients in the Lung cancer clinical trials.

At IAG, we design and implement protocols for thoracic CT images, assess the need for breath hold and use of intravenous contrast. We support image reconstruction, quality control and reading.

To optimise nodule detection, normally all baseline CTs are read by experienced thoracic radiologists; sometimes located in the local trial centres or at a central site. All discrepancies and adjudication is done by IAG’s imaging specialists.  It is common to ask the readers to identify and record all lung nodules greater than a certain size and diameter. We deploy volumetric measures whenever possible. Our measurements include the volume and maximum intensity projections (MIPs) to aid the detection.

MRI exams are done in addition to CT  when we are trying to assess the drug efficacy in a specific way, such as 1) resolution of the tumour invasion into the chest wall and the mediastinal structures (pancoast tumour); 2) impact on the solid and vascular hilar masses; 3) impact on the diaphragmatic abnormalities or when following-up mediastinal lymphoma.

MR exams are susceptible to motion artefacts such as breathing and require specific software to process. Recently, new applications, such as whole-body MR (WBMR) imaging are being deployed to assess metastatic disease. Diffusion weighted imaging (DWI) is used to assess changes in the tumour cellularity and the integrity of the cellular membrane. The DWI sequence is made susceptible to the differences in water mobility. The motion of water molecules is more restricted in tissues with a high cellular density associated with numerous intact cell membranes (e.g. tumour tissue). This technique can be applied for tumour detection and tumour characterisation and for the monitoring of response to treatment.

PET/CT is a combined imaging technique: CT giving anatomical information and PET giving metabolic information to detect lesions initially not seen on CT and to assess more precise localisation of lesions, delineate them from their surrounding structures and provide more accurate characterisation of a lesion as benign or malignant.

Reach out to our expert team, as you are designing and planning your trial.

About IAG, Image Analysis Group

IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development, and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.

Contact our expert team: imaging.experts @ ia-grp.com